UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for psoriasis and psoriatic arthritis in the United Kingdom. Explore treatment pathways including biologics, oral therapies, and novel agents.
Psoriasis affects ~1.8 million people in the UK (~2-3% of the population). It is an autoimmune condition causing red, scaly patches on the skin, often on elbows, knees, scalp, and lower back. About 30% of people with psoriasis develop psoriatic arthritis (joint inflammation). Psoriasis can significantly affect quality of life and is associated with increased cardiovascular risk.
Mild: topical treatments (vitamin D analogues, corticosteroids, coal tar). Moderate: phototherapy (UVB, PUVA). Moderate-severe: systemic therapies - methotrexate, ciclosporin, acitretin, or apremilast (Otezla). Severe: biologic therapies - anti-TNF (adalimumab, etanercept), anti-IL-17 (secukinumab, ixekizumab, brodalumab), anti-IL-23 (guselkumab, risankizumab, tildrakizumab), and anti-IL-12/23 (ustekinumab). NICE recommends biologics for patients with PASI >10 and DLQI >10 who have failed systemic therapy.
Active UK psoriasis trials include: next-generation IL-17/IL-23 inhibitors with longer dosing intervals, oral TYK2 inhibitors (deucravacitinib), JAK inhibitors for psoriatic arthritis, microbiome-based therapies, and precision medicine approaches. The British Association of Dermatologists runs major clinical trials through the UK Dermatology Clinical Trials Network.
We'll email you when new UK clinical trials start recruiting. Free, and you can unsubscribe anytime.
Free AI-powered matching - no signup required
